{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T15:40:27Z","timestamp":1770046827370,"version":"3.49.0"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,1,15]]},"DOI":"10.2169\/internalmedicine.7485-21","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T22:07:43Z","timestamp":1625868463000},"page":"217-221","source":"Crossref","is-referenced-by-count":7,"title":["Pneumocystis Pneumonia in a Patient with Ovarian Cancer Receiving Olaparib Therapy"],"prefix":"10.2169","volume":"61","author":[{"given":"Daisuke","family":"Himeji","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen-ichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuya","family":"Shiiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takamura","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotaka","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayaka","family":"Moriguchi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kousuke","family":"Marutsuka","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Fillatre P, Decaux O, Jouneau S, et al. Incidence of <i>Pneumocystis jiroveci<\/i> pneumonia among groups at risk in HIV-negative patients. Am J Med 127: 1242.e11-1242.e17, 2014.","DOI":"10.1016\/j.amjmed.2014.07.010"},{"key":"2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/esmoopen-2020-001110","volume":"5","author":"S Banerjee","year":"2020","unstructured":"2. Banerjee S, Gonzalez-Martin A, Harter P, et al. First-line PARP inhibitors in ovarian cancer: summary of an <i>ESMO Open - Cancer Horizons<\/i> round-table discussion. ESMO Open 5: 1-10, 2020.","journal-title":"ESMO Open","ISSN":"https:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Salzer HJF, Sch\u00e4fer G, Hoenigl M, et al. Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with <i>Pneumocystis jirovecii<\/i> pneumonia. Respiration 96: 52-65, 2018.","DOI":"10.1159\/000487713"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Azoulay \u00c9, Bergeron A, Chevret S, Bele N, Schlemmer B, Menotti J. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 135: 655-661, 2009.","DOI":"10.1378\/chest.08-1309"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tasaka S. Recent advances in the diagnosis and management of <i>Pneumocystis<\/i> pneumonia. Tuberc Respir Dis (Seoul) 83: 132-140, 2020.","DOI":"10.4046\/trd.2020.0015"},{"key":"6","unstructured":"6. Li WJ, Guo YL, Liu TJ, Wang K, Kong JL. Diagnosis of pneumocystis pneumonia using serum (1-3)-\u03b2-D-Glucan: a bivariate meta-analysis and systematic review. J Thorac Dis 7: 2214-2225, 2015."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Morris A, Norris KA. Colonization by <i>Pneumocystis jirovecii<\/i> and its role in disease. Clin Microbiol Rev 25: 297-317, 2012.","DOI":"10.1128\/CMR.00013-12"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Calder\u00f3n EJ. <i>Pneumocystis<\/i> infection: seeing beyond the tip of the iceberg. Clin Infect Dis 50: 354-356, 2010.","DOI":"10.1086\/649870"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tasaka S, Kobayashi S, Yagi K, et al. Serum (1\u21923) \u03b2-D-glucan assay for discrimination between <i>Pneumocystis jirovecii<\/i> pneumonia and colonization. J Infect Chemother 20: 678-681, 2014.","DOI":"10.1016\/j.jiac.2014.07.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of <i>Pneumocystis<\/i> pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and <i>Pneumocystis<\/i> pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 47: 915-923, 2008.","DOI":"10.2169\/internalmedicine.47.0702"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nakamura H, Tateyama M, Tasato D, et al. Clinical utility of serum \u03b2-D-glucan and KL-6 levels in <i>Pneumocystis jirovecii<\/i> pneumonia. Intern Med 48: 195-202, 2009.","DOI":"10.2169\/internalmedicine.48.1680"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Matsumura Y, Ito Y, Iinuma Y, et al. Quantitative real-time PCR and the (1\u21923)-\u03b2-D-glucan assay for differentiation between <i>Pneumocystis jirovecii<\/i> pneumonia and colonization. Clin Microbiol Infect 18: 591-597, 2012.","DOI":"10.1111\/j.1469-0691.2011.03605.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. <i>Pneumocystis carinii<\/i> pneumonia among patients without AIDS at a cancer hospital. JAMA J Am Med Assoc 267: 832-837, 1992.","DOI":"10.1001\/jama.267.6.832"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Watanabe M, Aoki Y, Kurata H, Tanaka K. <i>Pneumocystis carinii<\/i> pneumonia in a patient with stage IV ovarian cancer. Gynecol. Oncol. 87: 225-227, 2002.","DOI":"10.1006\/gyno.2002.6821"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Vananuvat P, Suwannalai P, Sungkanuparph S, et al. Primary prophylaxis for <i>Pneumocystis jirovecii<\/i> pneumonia in patients with connective tissue diseases. Semin Arthritis Rheum 41: 497-502, 2011.","DOI":"10.1016\/j.semarthrit.2011.05.004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tolaney SM, Najita J, Winer EP, Burstein HJ. Lymphopenia associated with adjuvant anthracycline\/taxane regimens. Clin Breast Cancer 8: 352-356, 2008.","DOI":"10.3816\/CBC.2008.n.041"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Waks AG, Tolaney SM, Galar A, et al. <i>Pneumocystis jiroveci<\/i> pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. Breast Cancer Res Treat 154: 359-367, 2015.","DOI":"10.1007\/s10549-015-3573-2"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by <i>BRCA<\/i> status in a randomised phase 2 trial. Obstet Gynecol Surv 69: 594-596, 2014.","DOI":"10.1097\/OGX.0000000000000107"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Shen M, Pan H, Chen Y, et al. A review of current progress in triple-negative breast cancer therapy. Open Med 15: 1143-1149, 2020.","DOI":"10.1515\/med-2020-0138"},{"key":"20","unstructured":"20. Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a <i>BRCA1\/2<\/i> mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18: 1274-1284, 2017."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381: 2416-2428, 2019.","DOI":"10.1056\/NEJMoa1911361"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/2\/61_7485-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T03:16:46Z","timestamp":1642216606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/2\/61_7485-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7485-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"article-number":"7485-21"}}